Differentiated miRNA expression and validation of signaling pathways in apoE gene knockout mice by cross-verification microarray platform

Hui Han¹, Yu-Hong Wang¹, Guang-Jin Qu¹, Ting-Ting Sun¹, Feng-Qing Li¹, Wei Jiang² and Shan-Shun Luo¹

The microRNA (miRNA) regulation mechanisms associated with atherosclerosis are largely undocumented. Specific selection and efficient validation of miRNA regulation pathways involved in atherosclerosis development may be better assessed by contemporary microarray platforms applying cross-verification methodology. A screening platform was established using both miRNA and genomic microarrays. Microarray analysis was then simultaneously performed on pooled atherosclerotic aortic tissues from 10 Apolipoprotein E (apoE) knockout mice (apoE⁻/⁻) and 10 healthy C57BL/6 (B6) mice. Differentiated miRNAs were screened and cross-verified against an mRNA screen database to explore integrative mRNA–miRNA regulation. Gene set enrichment analysis was conducted to describe the potential pathways regulated by these mRNA–miRNA interactions.

High-throughput data analysis of miRNA and genomic microarrays of knockout and healthy control mice revealed 75 differentially expressed miRNAs in apoE⁻/⁻ mice at a threshold value of 2. The six miRNAs with the greatest differentiation expression were confirmed by real-time quantitative reverse-transcription PCR (qRT–PCR) in atherosclerotic tissues. Significantly enriched pathways, such as the type 2 diabetes mellitus pathway, were observed by a gene-set enrichment analysis. The enriched molecular pathways were confirmed through qRT–PCR evaluation by observing the presence of suppressor of cytokine signaling 3 (SOCS3) and SOCS3-related miRNAs, miR-30a, miR-30e and miR-19b. Cross-verified high-throughput microarrays are optimally accurate and effective screening methods for miRNA regulation profiles associated with atherosclerosis. The identified SOCS3 pathway is a potentially valuable target for future development of targeted miRNA therapies to control atherosclerosis development and progression.

Experimental & Molecular Medicine (2013) 45, e13; doi:10.1038/emm.2013.31; published online 8 March 2013

Keywords: apolipoprotein E knockout mice; atherosclerosis; genome microarray; miRNA microarray; SOCS pathway

INTRODUCTION

Arteriosclerotic vascular disease (ASVD), commonly known as atherosclerosis, is a chronic inflammatory disease that affects both large and medium arteries. The disease is characterized by the involvement of numerous genes as well as varied environmental stimuli. Using gene-targeted or transgenic mice models, contemporary researchers have confirmed the roles of more than 80 individual genes in atherosclerosis progression and development.¹ Apolipoprotein E (apoE) has a central role in lipoprotein metabolism, where it is required for the efficient clearance of chylomicrons and very-low-density lipoproteins. Because of the unique role of apoE, Mice lacking apoE (apoE⁻/⁻) are well-established models, often used in studying lipoprotein metabolism and atherosclerosis.²

MicroRNAs (miRNAs) are small, noncoding RNAs with lengths of approximately 22 nucleotides. These molecules have critical roles in the regulation of many diverse biological pathways, including those associated with various pathologies.³,⁴ To date, over 1000 differentially expressed miRNAs in the human genome, only a small fraction of existent miRNAs, have been characterized and cataloged in the miRNA database (http://www.mirbase.org/). In developing tissues, miRNAs are differentially expressed at high dynamic ranges, and this variation in miRNA expression has been etiologically linked with numerous pathological conditions.⁵-⁷ The expression levels of at least 30% of all genes, including genes critical during differentiation processes in developing mammalian cells, are regulated by miRNAs. Notably, the expression levels
observed are highly specific to certain tissues, organs or cytotypes.8,9

Differential miRNA expression in clinical cardiovascular disease has been previously demonstrated in humans,10 where the most compelling evidence of miRNAs in endothelial cells originated as a byproduct of angiogenesis research. For instance, miRNA type miR-92a has been shown to inhibit angiogenesis, whereas miRNA type miR-126 has been shown to sustain vascular integrity and promote angiogenic signaling.7 Furthermore, localized miRNA expression profiles that may have a notable role in pathological occurrences vary dramatically between tissues of the heart and arteries,6 an observation that has recently been leveraged in research pertaining to vascular inflammation. In addition, the variant miRNA expression profiles observed in oxidized low-density lipoprotein (LDL)-stimulated human primary peripheral blood monocytes further confirms the role of these molecules in cardiovascular-related conditions.5 In rat models, variant miRNA expression profiles have been associated with the development of neointimal lesions of the carotid artery, a condition with distinctly different characteristics than related intimal hyperplasia processes.7 The recent elucidation of the mechanism of miR-10a regulation in proinflammatory phenotypes of prelesion atherosusceptible endothelium both in vivo and in vitro provides additional support for the importance of miRNAs in the management of arterial pathologies.11

Contemporary research has shown that miRNAs may have a more important role in disease onset and progression than originally suspected. Various miRNAs have been implicated in human diseases, such as cancer,12–14 developmental abnormalities,15 muscular diseases,16 and cardiovascular disorders.10,17 Only recently, however, has the importance of miRNAs in inflammatory diseases been recognized and characterized.18,19 Previous research has associated subtle variations in miRNA expression levels with numerous cardiovascular conditions. The seemingly ubiquitous involvement of miRNAs in cardiovascular pathologies suggests that a correlation likely exists between the expression of certain undetermined miRNAs and ASVD.

On the basis of these findings, atherosclerosis likely results in a specific pattern of miRNA and target mRNA expression. This hypothesis was evaluated by examining the miRNA regulation profile associated with atherosclerotic aortic plaques using simultaneous screening and cross-verification of apoE gene knockout (apoE−/−) mice and healthy C57BL/6 (B6) mice. Selective validation of miRNAs and enrichment of the interrelated molecular pathways associated with screened miRNAs and mRNAs provides a detailed regulatory profile of miRNAs in atherosclerosis development that are potentially useful for the development of new targeted therapies.

MATERIALS AND METHODS

Animal subjects

Ten male apoE−/− mice were constructed from mice of the C57BL/6 (B6) gene background (apoE−/− B6). Ten healthy, male control mice (B6) were obtained from the Experimental Animal Center at Peking University Health Science Center (Beijing, China). Mice were supplied with standard food containing 6.5% fat, 19.5% protein and no cholesterol (Keao Xieli Feed, Beijing, China), as well as untreated tap water ad libitum throughout the study. All food was sterilized by irradiation (4%Co) before feeding (Keao Xieli Feed). All mice were killed at the age of 8 months. The study was approved by the Ethical Committee of Harbin Medical University, and was conducted in adherence to all applicable state and university guidelines.

Aortic tissue isolation and staining

At 8 months of age, all mice were anesthetized with sodium pentobarbital (Nembutal, 75 mg kg−1, intraperitoneal), and phosphate-buffered saline containing 5 U ml−1 of heparin was poured through the left ventricle of the heart. Under a stereomicroscope (Olympus SZX-ZB7; Olympus, Tokyo, Japan), the aorta was carefully excised. Aortic segments were immediately stored in liquid nitrogen for further analysis.

Hematoxylin and eosin staining was used to visualize tissue samples. Briefly, proximal aorta samples were prepared by careful dissection and followed by continuous fixation in 4% paraformaldehyde in 0.1 mol l−1 phosphate buffer (pH 7.4) for 24 h. Samples were then immersed for 15 min in a buffer solution containing 10% sucrose, and for 30 min in a buffer containing 20% sucrose. Samples were then embedded in optical coherence tomography compound (Tissue-Tek; Milestone Laboratories, Elkhart, IN, USA) and snap-frozen. Transverse sections with 10 μm thicknesses were stained with hematoxylin and eosin and Oil Red O for further microscopic examination.

Total RNA isolation

Total RNA from each aortic segment was collected using TRIzol (Invitrogen, Carlsbad, CA, USA) and a miRNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Following RNA quantification using the NanoDrop 1000 (Thermo-Fisher Scientific, Wilmington, DE, USA), equal amounts of RNA from healthy aortic wall samples of apoE−/− and B6 mice were divided into the atherosclerotic group (A) and normal group (N).

Microarray and analysis of miRNA

A and N samples were labeled using the miRCURY Hy3/Hy5 Power Labeling Kit (Exiqon, Vedbaek, Denmark) and hybridized on the miRCURY LNA Array v.16.0 (Exiqon). After washing, slides were scanned using the Axon GenePix 4000B microarray scanner (Axon Instruments, Foster City, CA, USA). Scanned images were then imported into GenePix Pro 6.0 software (Axon) for grid alignment and data extraction. Replicated miRNAs were averaged, and miRNAs with intensities >50 in all samples were used in the calculation of a normalization factor. Expression data were normalized using the median normalization value. After normalization, differentially expressed miRNAs were identified through fold-change filtering.

Microarray of mRNAs

The RNA integrity of A and N samples was then assessed by standard denaturing agarose gel electrophoresis. Approximately 5 μg of the total RNA from each sample was used for labeling and array hybridization. Reverse transcription was completed using a SuperScript double stranded cDNA Synthesis Kit (Invitrogen) followed by double stranded cDNA labeling using a NimbleGen One-color DNA Labeling Kit (Roche Diagnostics GmbH, Mannheim, Germany),
Differential expression of miRNAs between B6 and apoE−/− mice aortic walls

Following normalization, the average values for each miRNA cluster were used for statistical analysis. A total of 75 miRNAs were differentially expressed in the apoE−/− mouse aorta samples, of which 30 demonstrated upregulation. Among these upregulated miRNAs, the most dramatic differentiation expressions were observed for mmu-miR-34a (37.8-fold increase), mmu-miR-465c-5p (21.7-fold increase) and mmu-miR-9* (21.3-fold increase; Table 1). Among the other 45 downregulated miRNAs, the largest decreases in expression were observed in mmu-miR-30e (25-fold decrease), mmu-miR-29a (16.7-fold decrease) and mmu-miR-669n (12.5-fold decrease).
decrease) (Table 2). On the basis of the differential expressions observed in these miRNAs, a heat map was generated to indicate distinguishable miRNA expression profiles between apoE−/− and normal B6 aortic tissues (Figure 2).

Validation of microarray results using qRT–PCR
Microarray results were validated by qRT–PCR analysis of apoE−/− and B6 aortic tissue microarray results for miRNA types mmu-miR-34a, mmu-miR-465c-5p, mmu-miR-9*, mmu-miR-30e, mmu-miR-29a and mmu-miR-669n. RNA samples from all apoE−/− and B6 samples were pooled for this analysis. In affected tissues, the expression levels of mmu-miR-34a, mmu-miR-465c-5p and mmu-miR-9* were upregulated, whereas the expression levels of mmu-miR-30e, mmu-miR-29a and mmu-miR-669n were downregulated. All the six examined miRNAs demonstrated comparable expression levels by both microarray and qRT–PCR analyses (Figure 3). These findings further confirm that atherosclerosis-related miRNAs may participate in ASVD.

Differential gene expression between B6 and apoE−/− aortic tissues
The appearance of a twofold (200%) change in filtering was used as the criteria for differential expression. Of the 44 170 gene sequences evaluated, differential expression levels in B6 and apoE−/− aortic tissue arrays were observed in 2283 genes. Among these genes, 1480 genes demonstrated increased expression in apoE−/− mice relative to healthy controls (upregulation >200%), and 803 genes demonstrated decreased expression in apoE−/− mice relative to healthy controls (downregulation by >50%).

Functional enrichment analysis for differentially expressed miRNAs
A total of 400 genes were identified as part of the refined gene set, each serving as a target gene for a specific miRNA. In atherosclerotic apoE−/− aortic tissues, 75 differentially expressed miRNAs that exhibited a negative correlation with regulated miRNAs were identified. Using these genes, significantly enriched type 2 diabetes mellitus pathways (P<0.01) were identified. The miRNAs regulating the refined genes in this pathway exhibited an inverse expression pattern when compared with the refined genes of the pathway shown in Table 3. The miRNA–mRNA interaction network associated with type 2 diabetes pathway is further detailed in Figure 4.

Table 1 Upregulation of miRNAs in atherosclerotic tissue

| Accession number | Name            | Fold change (A/N) |
|------------------|-----------------|-------------------|
| M10000584        | mmu-miR-34a     | 35.8              |
| MIMAT0004873     | mmu-miR-465c-5p | 21.7              |
| MIMAT000143      | mmu-miR-9*      | 11.3              |
| MIMAT0004572     | mmu-miR-290-3p  | 11.1              |
| M10001524        | mmu-miR-431     | 5.6               |
| MIMAT0000527     | mmu-miR-16      | 4.9               |
| MIMAT0016996     | mmu-miR-185*    | 3.7               |
| MIMAT0003783     | mmu-miR-615-3p  | 3.6               |
| M10004516        | mmu-miR-763     | 3.6               |
| M10000569        | mmu-miR-21      | 3.4               |
| M10000233        | mmu-miR-191     | 3.0               |
| MIMAT0004525     | mmu-miR-99b*    | 2.8               |
| MIMAT0017330     | mmu-miR-669e*   | 2.8               |
| MIMAT0004790     | mmu-miR-503*    | 2.7               |
| MIMAT0003725     | mmu-miR-675-5p  | 2.7               |
| M10000792        | mmu-miR-375     | 2.7               |
| MIMAT004524      | mmu-miR-30b*    | 2.6               |
| MIMAT0004850     | mmu-miR-833b-5p | 2.5               |
| MIMAT0004524     | mmu-miR-669*    | 2.4               |
| M10004689        | mmu-miR-705     | 2.3               |
| M10004134        | mmu-miR-668     | 2.3               |
| M10004695        | mmu-miR-711     | 2.3               |
| MIMAT0017235     | mmu-miR-758*    | 2.3               |
| MIMAT0017234     | mmu-miR-592*    | 2.2               |
| M10009949        | mmu-miR-1954    | 2.2               |
| MIMAT0004871     | mmu-miR-465b-5p | 2.2               |
| MIMAT0005292     | mmu-miR-582-3p  | 2.1               |
| MIMAT0017015     | mmu-let-7a-2*   | 2.1               |
| M10000698        | mmu-miR-214     | 2.0               |
| M10003538        | mmu-miR-503     | 2.0               |

Abbreviation: miRNA, microRNA.
Note: Accession number, miRNA no. in miRBase; Name, alphanumerical call sign for miRNA; Fold change (A/N), miRNA expression ratio of atherosclerotic/normal.
The expression levels of these miRNAs in seven individual samples from each group were further analyzed by qRT–PCR, demonstrating that mmu-mir-30a, mmu-mir-30e and mmu-mir-19b expression levels were significantly lower in apoE−/− aortic tissues than the levels observed in healthy controls (P<0.01; Figure 5). In addition, the SOCS3 mRNA and protein expression levels in each group were further analyzed by qRT–PCR and western blot. As a result, SOCS3 expression levels were shown to be significantly higher in apoE−/− aortic tissues than the levels observed healthy controls (Figures 6 and 7).

**DISCUSSION**

Six specific miRNAs associated with ASVD were identified using high-throughput miRNA microarray analysis. These miRNAs may provide novel biomarkers for artherosclerosis disease progression useful in development of future targeted therapies. When coupled with contemporary miRNA-target prediction programs and gene expression profiles (mRNA), miRNA profiling offers a unique new strategy for addressing ASVD development and progression in both research and clinical settings. The initial step in realization of the immense clinical potential of the miRNAs associated with atherosclerotic regulation is the full characterization of these miRNAs and their affected pathways, a process that began in the current study.

Comparison of miRNA levels observed in atherosclerotic and normal aortic tissues of the mouse ASVD model provides useful information on miRNA regulation in atherosclerosis. The earliest mouse models of atherosclerosis, developed by Wissler in the 1960s, were diet-induced.21 These models were inaccurate because the diet was shown to be in itself inflammatory in mice, inducing hepatic nuclear factor-κB activation and the expression of acute-phase reactants associated with artherosclerosis.22 In 1992, apoE−/− mice were first generated by inactivating the ApoE gene by targeting.23 Notably, the apoE−/− mouse used in the current study was the first model developed that showed severe and rapid development of atherosclerotic plaques without dietary intervention.24,25 In genetically homozygous mice, this model limits the errors in dietary models caused by very small lesion size and confinement of lesions to the aortic root, often resulting in failure to develop beyond early foam-cell, fatty-streak stages.21 The homozygous apoE−/− mice used in the current study exhibited only a single phenotype pertinent to the study of atherogenesis, resulting in similar body weight and health, but distinct lipid and lipoprotein profiles compared with normal mice of the same species. Previous studies have established the use of the apoE-deficient models apoE−/− and nlrp3−/−, apoE−/− and asc−/−, and apoE−/− and caspase-1−/−, demonstrating negligible phenotypical variation in the parameters associated with artherosclerosis, including disease progression, infiltration of plaques by macrophages and plaque stability in all the apoE−/− models. Notably, the same study also revealed four variant genotypes through smooth muscle actin staining.26

### Table 2 Downregulation of miRNAs in atherosclerotic tissue

| Accession number | Name       | Fold change (N/A) |
|------------------|------------|-------------------|
| M10000359        | mmu-mir-30a | −25.0             |
| M10000576        | mmu-mir-29a | −16.7             |
| M10009951        | mmu-mir-669n| −12.5             |
| MIMAT004825      | mmu-mir-423-5p| −10.0           |
| MIMAT000670      | mmu-mir-222 | −8.3              |
| M1000221         | mmu-mir-10a | −8.3              |
| MIMAT004536      | mmu-mir-151-5p| −7.8           |
| MIMAT000136      | mmu-mir-125b-5p| −7.1          |
| MIMAT000210      | mmu-mir-181a| −7.1              |
| M10006301        | mmu-mir-467g| −7.1              |
| M1000405         | mmu-let-7d  | −6.7              |
| M10000571        | mmu-mir-23a | −6.7              |
| M10014047        | mmu-mir-3084| −6.7              |
| M1000235         | mmu-mir-193 | −5.6              |
| MIMAT000521      | mmu-let-7a  | −5.6              |
| M1000144         | mmu-mir-30a | −4.2              |
| M1000137         | mmu-let-7g  | −4.0              |
| M10004693        | mmu-mir-709 | −3.8              |
| M1000293         | mmu-mir-467f| −3.7              |
| M1000407         | mmu-mir-106b| −3.7              |
| MIMAT000137      | mmu-mir-126-5p| −3.7         |
| M1000564         | mmu-mir-15a | −3.4              |
| MIMAT000711      | mmu-mir-365 | −3.4              |
| M1000690         | mmu-mir-706 | −3.3              |
| M1000156         | mmu-mir-130a| −3.1              |
| M1000257         | mmu-mir-143 | −3.0              |
| M10000575        | mmu-mir-26b | −3.0              |
| M1000695         | mmu-mir-210 | −2.9              |
| MIMAT000513      | mmu-mir-19b | −2.8              |
| M1000558         | mmu-let-7b  | −2.7              |
| M1000138         | mmu-let-7i  | −2.6              |
| MIMAT000138      | mmu-mir-126-3p| −2.6          |
| MIMAT0017323     | mmu-mir-669k | −2.6            |
| M1000169         | mmu-mir-145 | −2.6              |
| MIMAT000523      | mmu-let-7c  | −2.6              |
| MIMAT0017255     | mmu-mir-491* | −2.5            |
| M1000237         | mmu-mir-195 | −2.5              |
| M1000174         | mmu-mir-152 | −2.4              |
| MIMAT000536      | mmu-mir-29c | −2.4              |
| M1000146         | mmu-mir-99a | −2.4              |
| MIMAT0017002     | mmu-mir-204*| −2.4              |
| MIMAT0003780     | mmu-mir-490-3p| −2.3           |
| MIMAT000546      | mmu-mir-103 | −2.3              |
| M1000570         | mmu-mir-22  | −2.2              |
| M10004673        | mmu-mir-669c| −2.0              |

**Abbreviation:** miRNA, microRNA.

**Note:** Accession number, miRNA no. in miRBase; Name, alphanumerical call sign for miRNA; Fold change (N/A), miRNA expression ratio of normal/atherosclerotic.
Although apoE−/− mice have been shown to be genetically inclined to hypercholesterolemia on high-fat diets and interleukin-1α, not interleukin-1β, most significantly contributes to atherosclerosis pathogenesis, these genotypic variations are not significantly expressed in the phenotype of apoE−/− mice. 26, 27 Thus, the apoE−/− mice in the present study were phenotypically equivalent in terms of atherosclerotic features.

In the current study, differential expression was observed in 75 of 1891 examined miRNAs by comparing atherosclerotic and normal aortic tissues using an miRNA microarray platform. Of these, 45 miRNAs were significantly downregulated and 30 were upregulated in atherosclerotic aortic tissues, indicating the significant involvement of miRNAs in ASVD tissues. Furthermore, the current study was also able to confirm previous findings that miR-34a and miR-21 are highly upregulated in atherosclerotic plaques compared with the levels observed in healthy arteries. 28 The upregulation of miR-21, miR-214, miR-9 and miR-99b coupled with the downregulation of miR-423-5p, miR-15a, miR-143 and miR-145 expression shown in the present study also confirms the previously reported findings of Chen et al. 5 in a study of oxidized LDL-stimulated human primary monocytes. 10 The downregulation of miR-10a in apoE−/− aortic tissues is also consistent with previous observations of atherosusceptible arterial endothelial tissues in swine, in which notable up- and downregulation of certain miRNAs was observed. 7

Although exploration of the breadth of miRNAs impacting pathological conditions like ASVD has only recently begun, contemporary data suggests that miR-155 has a distinct expression profile. In fact, it may have a crucial role in various physiological and pathological processes, such as hematopoietic lineage differentiation, immunity, inflammation, cancer and cardiovascular disease. 29 It has also been reported that miR-155 silencing enhances both the inflammatory response and lipid uptake in oxidized LDL-stimulated human THP-1 macrophages. 30 Results of the current study show, however, that miR-155 is slightly increased in atherosclerotic tissues compared with control tissues. This increase occurs at a rate 1.31-fold higher than in normal tissues, confirming the previously speculative association between this miRNA and ASVD. Furthermore, Chen et al. 5 previously reported that miR-125a-5p serves as a partial regulator of the inflammatory response, lipid uptake and oxidized LDL-stimulated...
Table 3 Significantly enriched KEGG pathways in the refined gene set

| Significant pathways | Refined pathway genes | Negatively regulated miRNAs | P-value  |
|----------------------|-----------------------|-----------------------------|----------|
| Type II diabetes mellitus | MAPK1, SOCS3, PIK3CD, MAPK10, PRKCD, PIK3R2 (six genes) | mmu-miR-181a, mmu-miR-145, mmu-miR-19b, mmu-miR-30a, mmu-miR-30e, mmu-miR-222, mmu-miR-26b (7 miRNAs) | 0.00961 |

Abbreviation: KEGG: Kyoto Encyclopedia of Genes and Genomes.

The miRNAs that regulate the refined genes in the type 2 diabetes pathway show an inverse expression pattern compared with the refined genes in the pathway shown in Table 3; P-values are a result of the enrichment analysis. Note: The significant KEGG pathways in which the refined gene set was enriched are shown.

The potential for variation in miRNA expression is particularly high when examining aortic tissues due to the many cytotypes found in the aorta, including endothelial cells, macrophages, smooth muscle cells and fibroblasts. Each of these cytotypes also adds significant complexity to the regulatory progress, making full characterization of these compounds difficult to elucidate. Novel miRNA-mediated regulatory mechanisms associated with ASVD and lipoprotein metabolism have been determined by miRNA profiling coupled with functional testing. It should be noted, however, that simple steady-state expression profiling of miRNAs and mRNAs present several limitations, including an inability to observe active Ago-complexed miRNAs or repressed mRNAs. Thus, future studies are required to determine the precise components and mechanisms responsible for miRNA expression level variations in human ASVD before therapeutic use is possible. Notably, the study of animal models provides an effective means for perfecting miRNA isolation methods and

**Figure 5**
Expression of miR-30a, miR-30e and miR-19b in atherosclerotic and normal aortic tissues were evaluated by TaqMan quantitative reverse-transcription PCR (qRT–PCR), revealing downregulation of these microRNAs (miRNAs) in apolipoprotein E knockout (apoE–/–) aortic tissues compared with levels observed in B6 control aortic tissues. The expression values for the B6 controls were set at 1. Data are indicated as means ± s.d. of seven individual subjects; *P<0.05 versus B6 controls.

**Figure 6**
Expression of suppressor of cytokine signaling-3 (SOCS3) mRNA in atherosclerotic (apolipoprotein E knockout (apoE–/–)) and control (B6) aortic tissues is shown. The expression values for the B6 controls were set at 1. Data are indicated as the means ± s.d. of seven individual subjects; P<0.01 versus B6 controls.

**Figure 7**
(a) The expression of suppressor of cytokine signaling-3 (SOCS3) proteins extracted from aortic tissues and examined by western blotting. (b) Intensities of the bands corresponding to SOCS3 and β-actin (a) were determined densitometrically. The intensity values of SOCS3 normalized to β-actin are shown. Notably, protein samples obtained from two independent experiments were subjected to western blot analysis, demonstrating similar results.
generating useful potential biomarkers, many of which may appear analogously in humans and other mammalian cells. By analyzing predicted miRNA targets using miRecords, 400 differentially expressed target genes were identified as negatively regulated by the 75 miRNAs isolated in the present study. The Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis identified enriched type 2 diabetes mellitus pathways associated with ASVD, findings that are concurrent with recent studies. The current findings also support the previously observed association between type 2 diabetes mellitus and ASVD.\textsuperscript{31} In diabetic patients, signal transduction in atherosclerosis increase the risk of developing ASVD.\textsuperscript{32–34} Similarly, insulin has a key role in the pathogenesis of both type 2 diabetes mellitus and ASVD,\textsuperscript{32} as exhibited by the upregulation of SOCS3 and downregulation of the SOCS3 negative-mediator miRNAs (miR-19b, miR-30a and miR-30e) currently observed in ASVD tissues. This phenomenon may also be observed in the enriched type 2 diabetes mellitus pathway.

Numerous processes involved in atherosclerosis are governed by miRNAs. During atherosclerosis, macrophages engulfed with cholesterol undergo a complete gene profile and phenotypic conversion to foam cells.\textsuperscript{3} The miRNAs miR-125a-5p, miR-146a, miR-146b-5p, miR-155 and miR-9 have all been shown to be significantly upregulated in response to oxidized LDL during this process. Thus, vascular cellular proliferation and inflammation involving these cytotopes are likely atherosclerotic processes governed by miRNAs. Other processes, such as calcification, plaque vulnerability and thrombosis may also be affected, though full investigation of these mechanisms has not yet been conducted.\textsuperscript{35} Significantly lower expressions of miR-19b, miR-30a and miR-30e were observed in atherosclerotic tissues than in healthy control tissues using qRT–PCR (Figure 5), findings consistent with previous reports showing that miR-30a inhibits processes of invasion and metastasis,\textsuperscript{32} that the miR-30 gene family has a central role in adipocyte development\textsuperscript{34} and that miR-19b inhibits angiogenesis by blocking cell cycle progression in endothelial cells.\textsuperscript{36} Further studies will be required to prove that these miRNAs are, in fact, associated with the predicted target gene SOCS3. The current experimental results, however, suggest that this association is likely through evidence that the SOCS3 gene mRNA and proteins were increased in atherosclerotic tissues (Figures 6 and 7). Furthermore, previous findings of increased SOCS3 expression in aortic lesions of apoE\textsuperscript{−/−} mice\textsuperscript{37,38} and associations with atherosclerosis development\textsuperscript{39} were supported by the present results. Thus, miRNAs are likely to have a role in the development of atherosclerosis via regulation of SOCS3 or interactions with SOCS3-related pathways.

The SOCS pathway is an endogenous anti-inflammatory, anti-apoptotic pathway closely related to ASVD development. It acts as a negative regulator of the JAK/signal transducer and activator of transcription (STAT) signaling pathway that functions in the stress response signaling pathway involved in cell proliferation, apoptosis and differentiation. The SOCS pathway regulates these processes in many different cytotypes, including vascular endothelial cells, smooth muscle cells and macrophages. It also participates in the formation of atherosclerotic plaques. JAK/STAT-associated genes have been shown to modify granulopoiesis and neutrophil immune functions through the SOCS, and STAT pathways. Moreover, activation of the JAK/STAT pathways may sometimes rescue neutrophils from apoptosis. By inhibiting the JAK/STAT signaling pathway, SOCS proteins can reduce the expression of inflammatory factors and apoptotic genes. Another important ability of SOCS proteins is inhibition of cell proliferation or apoptosis, thereby maintaining the dynamic equilibrium required for normal cell function and activity. Aside from the three identified SOCS3-related miRNAs, other ASVD-related miRNAs may also be involved in the regulation of ASVD. The discovery of specific miRNA involvement in SOCS regulation suggests that it may be possible to develop therapeutics that regulate SOCS expression and inhibit the cytokine signaling pathway. Such techniques may provide a clinically viable method for reducing the development and progression of ASVD in human patients in the future.

The current findings provide a comprehensive characterization of miRNA expression in ASVD; however, detailed information pertaining to miRNAs and their target functions in specific cell types remains to be elucidated in a more controlled setting. As numerous cytotypes are present in aortic tissues, often exhibiting very different miRNA expression levels, it is important to note that the current sampling methods may have affected the outcomes of the present study. These samples were taken from the arterial intima and inner media layer, enabling the conclusion that this miRNA profile is representative of tissue changes in the diseased artery itself instead of merely the intimal plaque. These results, however, must be interpreted with caution, as the contributions of processes in the outer media and adventitia cannot be completely precluded by current methods, necessitating methods with greater control for future work. In addition, these results should be validated by further examination of immunohistochemical characteristics and lesion morphology. Pre-\textsuperscript{}viously, apoE\textsuperscript{−/−} mice have been shown to have abnormal T lymphocytes levels\textsuperscript{40} and differences in antibody affinities\textsuperscript{41} compared with normal mice. Although lymphocytes have not been reported in atherosclerotic lesions in apoE\textsuperscript{−/−} mice models, the B lymphocytes CD4\textsuperscript{+}, CD8\textsuperscript{+} and CD23\textsuperscript{+} have been demonstrated in aortic fatty streaks in vasculitis-prone MRL/lpr mice.\textsuperscript{12} This further necessitates future immunohistochemical studies to support the present findings. Similarly, the current methods used for detection of miRNA effects on target gene expression were conducted at the mRNA level. In future studies, more physiologically correct results could be achieved by examining the protein level following mRNA translation.

**CONCLUSION**

A total of 75 differentially expressed miRNAs were identified in atherosclerotic aortic tissues taken from mouse models. These
tissues showed unique miRNA expression profiles that will be of interest to future researchers examining the pathophysiology of atherosclerosis. The current work applied cross-verification to confirm that SOCS3 and the SOCS3-related miRNAs, miR-30a, miR-30e and miR-19b, are potential diagnostic biomarkers with likely involvement in many of the pathways contributing to ASVD development and progression. Further investigation will, however, be required to clarify the exact roles had by specific miRNAs in the pathogenic process of ASVD. Characterization of these miRNAs provides a basis for the future development of potentially useful miRNA-based therapeutics for improved clinical diagnosis, treatment and prognosis in atherosclerosis patients.

ACKNOWLEDGEMENTS
This work was supported by grants from the National Natural Science Foundation of China (number 81070216), Heilongjiang Provincial Education Department Foundation of China (number 1156z002), Ministry of Education ‘Chunhui plan’ (number Z2010007) and the Funds of the First Affiliated Hospital of Harbin Medical University (number 2009F01). Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.

1 Wang X, Ishimori N, Korstanje R, Rollins J, Paigen B. Identifying novel Cheng Bio-tech, Shanghai, China. Microarray experiments were performed by Kang Cheng Bio-tech, Shanghai, China.
modulate JAK/STAT-mediated cell responses during atherosclerosis. *Arterioscler Thromb Vasc Biol* 2009; **29**: 525–531.

38 Xu X, Wang Q, Deng B, Wang H, Dong Z, Qu X et al. Monocyte Chemoattractant Protein-1 Secreted by Decidual Stromal Cells Inhibits NK Cells Cytotoxicity by Up-Regulating Expression of SOCS3. *PloS One* 2012; **7**: e41869.

39 Tang J, Kozaki K, Farr AG, Martin PJ, Lindahl P, Betsholtz C et al. The absence of platelet-derived growth factor-B in circulating cells promotes immune and inflammatory responses in atherosclerosis-prone ApoE −/− mice. *Am J Pathol* 2005; **167**: 901–912.

40 Qiao JH, Xie PZ, Fishbein MC, Kreuzer J, Drake TA, Demer LL et al. Pathology of atheromatous lesions in inbred and genetically engineered mice. Genetic determination of arterial calcification. *Arterioscler Thromb* 1994; **14**: 1480–1497.

41 Roselaar SE, Kakkathathu PX, Daugherty A. Lymphocyte populations in atherosclerotic lesions of apoE −/− and LDL receptor −/− mice. Decreasing density with disease progression. *Arterioscler Thromb Vasc Biol* 1996; **16**: 1013–1018.

42 Qiao JH, Castellani LW, Fishbein MC, Lusis AJ. Immune-complex-mediated vasculitis increases coronary artery lipid accumulation in autoimmune-prone MRL mice. *Arterioscler Thromb* 1993; **13**: 932–943.